Addressing the Challenges in Downstream Processing Today and Tomorrow - Newer classes of biotherapies will require innovations in processing technology. - BioPharm International

ADVERTISEMENT

Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.


BioPharm International Supplements
Volume 24, Issue 4, pp. s8-s15

REFERENCES

1. C. Scott, Bioprocess Intl. 7 (10, Suppl.), (2009).

2. G. Walsh, Eur. J. Pharm. Biopharm. 55 (1), 3–10 (2003).

3. X. Wang et. al., mAbs. 1 (3), 254-267 (2009).

4. G. Jagschies et. al., BioPharm. Int. 19 (June Suppl.), 10–19 (2006).

5. J. R. Birch and A. J. Racher. Adv. Drug Deliv. Rev. 58 (5–6), 671-685 (2006).

6. B.D. Kelley, mAbs 1 (5), 1–10 (2009).

7. B.D. Kelley et.al., Biotechnol. Bioeng, 101 (3), 553–566 (2008).

8. J.L. Coffman, J.F. Kramarczyk, and B.D. Kelley, Biotechnol. Bioeng. 100 (4), 605–618 (2008).

9. B.D. Kelley et. al., Biotechnol. Bioeng. 100 (5), 950–963 (2008).

10. J. Glynn et. al., BioPharm. Int. 22 (October Suppl.), 15-19 (2009).

11. E.J. Suda, et. al., J. Chromatogr. A. 1216 (27), 5256–5264 (2009).

12. B. Kelley, Biotechnol. Prog. 23 (5), 995–1008 (2007).

13. G.R. Bolton, J. Basha, and D.P. LaCasse, Biotechnol. Prog. 26 (6), 1671–1677.

14. C. Winter, US patent 0237762 (2007).

15. G.R. Bolton, H. Araya, and A.W. Boesch, "Membrane Evaporation for Generating Highly Concentrated Protein Therapeutics" International Patent Application WO 2010/111378 A1.

16. M. Shamashkin et. al., Recovery of Biological Products XIV, (Lake Tahoe, CA 2010)

17. A.L. Nelson, E. Dhimolea, and J.M. Reichert, Nat. Rev. Drug. Discov. 9, 767–74 (2010).

18. G. Walsh, Nat. Biotechnol. 29 (9), 917–924 (2010).

19. C. Sheridan, Nat. Biotechnol. 28 (4), 307-310 (2010).

20. G. Walsh, BioPharma. Int. 23 (10), 1–8 (2009).

21. A.L. Nelson and J.M. Reichert, Nat. Biotechnol. 27 (4), 331–337 (2009).

22. M.D. Zolodz et. al., J. Chromatogr. A. 1217 (2), 225–234 (2010).

23. B.N. Violand. "Initial purification of inclusion bodies," in Protein Purification Applications, S. Roe, Ed. (Oxford University Press, Oxford, UK, 2nd ed. 2001), pp. 19–27.

24. J.J. Buckley, S.D. Hoeltzli, and G.V. Johnson, Biotechnol. Appl. Biochem. 56 (1), 27–34 (2010).

25. V. Dechavanne et. al., Protein Expr. Purif. 75 (2), 192–203 (2011).

26. S.C. Alley, N.M. Okeley, and P.D. Senter, Curr. Opin. Chem. Biol. 14 (4), 529–537 (2010).

27. C.F. McDonagh et. al., Protein Eng. Des. Sel. 19 (7), 299–307 (2006).

28. J.R. Junutula et. al., Nat. Biotech. 26 (8), 92–-932 (2009).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here